Certified by Founder Lodge
RA Capital Management, L.P.
United States - Boston, MA
INVESTOR
1 Disclosed Funding Rounds $160,000,000
164 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing
| Company | Date | Round | Raised |
|---|---|---|---|
 Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
 Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
 Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
 Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
 ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
 Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
 Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
 Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
 NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
 Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
 Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
 Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
 Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
 SpyGlass Pharma, Inc. |
July, 11 ,2023 | Series C | $90,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Pluton Biosciences |
May, 25 ,2023 | Series A | $16,500,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
 Nature's Toolbox, Inc. (NTx) |
November, 17 ,2023 | Series B | $47,500,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| SpyGlass Pharma, Inc. |
July, 11 ,2023 | Series C | $90,000,000 |
| ExcepGen |
August, 25 ,2023 | Unknown | $4,000,000 |
| NAPIGEN, INC. |
July, 12 ,2022 | Seed | $7,900,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Vaxess Technologies |
September, 14 ,2023 | Unknown | $9,000,000 |
| Commons Clinic |
October, 10 ,2023 | Series A | $19,500,000 |
| Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
| Abcuro, Inc |
August, 18 ,2023 | Series B | $155,000,000 |
| SpyGlass Pharma, Inc. |
July, 11 ,2023 | Series C | $90,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
| Superluminal Medicines Inc. |
September, 04 ,2023 | Seed | $33,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
Balerion AI | $6,000,000 | (Apr 17, 2026)
Solidroad | $25,000,000 | (Apr 17, 2026)
Worki.ai | $2,750,000 | (Apr 17, 2026)
Beeline Medicines | $300,000,000 | (Apr 17, 2026)
Ethermed | $8,500,000 | (Apr 17, 2026)
